Follow on Google News News By Tag Industry News Country(s) Industry News
Follow on Google News | Biomedical Stock News: (PWRM) (CSBR) & ( UGNE)has been trading in a channel. Pay attention for a possible breakout. PWRM deserves to be watched very closely! A breakout could be an indicator of possible momentum.
By: crwepicks Last: PWRM is now available for $0.039 cents a share. Since the beginning of June 2010 PWRM has been trading in a channel. Pay attention for a possible breakout. PWRM deserves to be watched very closely! A breakout could be an indicator of possible momentum. PWRM pursues an aggressive intellectual property strategy to protect its inventions and discoveries made on its own and with its collaborators. Power3 Medical works with key physician scientists at major medical research and treatment centers. With access to decisive human clinical samples and superior trade secret proteomic methodologies, the Company provides solutions to pressing challenges in diagnosis and treatment of patients and has concluded research agreements, technology license agreements, and filed provisional and utility patents. Power3 is also adding additional layers of research and license agreements, patent filings, and trade secrets, as its technology and product portfolio develops, to cover: Processes - The manner in which the discoveries are made and tests developed Discoveries - Protein disease footprints, Products - Early detection tests, Biomarkers, and Drug Targets The intellectual property that Power3 has and continues to pursue today covers the product areas of breast cancer, neurodegenerative diseases, and drug resistance: The intellectual property that Power3 has and continues to pursue today covers the product areas of breast cancer, neurodegenerative diseases, and drug resistance as depicted below: Two of Power3 Medical Areas of Research Breast Cancer Power3’s early indication breast cancer NAF protein footprint test More than 120 identified NAF protein biomarkers and drug targets for early indication and treatment of breast cancer NAF footprints for individualized therapy Neurodegenerative Diseases - ALS (Lou Gehrig’s Disease), Alzheimer’s Disease, Parkinson’s Disease, Other Neurological Disorders Power3’s blood serum test for distinguishing between the neurodegenerative diseases Blood serum biomarkers and drug targets for neurodegenerative disease Resistance to Chemotherapy Power3’s test for prediction of response to drug therapy in cancer Biomarkers and drug targets for treatment and monitoring of drug resistance Continue your research at www.power3medical.com ________________________________________________ Champions Biotechnology Inc. (CSBR.OB) Last: $0.90 Champions Biotechnology Inc. is a biotechnology company that engages in the development of advanced preclinical platforms and predictive tumor specific data to enhance the value of oncology drugs in the United States. Its preclinical platform is an approach based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting xenografts (Biomerk Tumorgrafts) Visit: http://www.championsbiotechnology.com ________________________________________________ Unigene Laboratories Inc. (UGNE.OB) Last: $0.80 Recent news: Unigene Appoints New CEO, Ashleigh Palmer Unigene Laboratories Inc. engages in the research, production, and delivery of peptides for medical use primarily in the United States. The company focuses on the development of calcitonin and other peptide products for the treatment of osteoporosis and other indications, including nasal and oral calcitonin, and oral parathyroid hormone (PTH). It offers Fortical, a nasal calcitonin product for the treatment of postmenopausal osteoporosis. Unigene Laboratories has licensing agreements with GlaxoSmithKline to develop an oral formulation of an analog of PTH; Upsher-Smith Laboratories Inc. to market Fortical; Novartis Pharma AG to manufacture calcitonin; and Tarsa Therapeutics, Inc. to develop Phase III oral calcitonin program. It also has a joint venture agreement with Shijiazhuang Pharmaceutical Group Company, Ltd. for the research, development, and manufacture of recombinant salmon calcitonin and non-oral PTH. The company was founded in 1980 and is based in Boonton, New Jersey. Visit: http://www.unigene.com ******************************************* Sign-Up For Free Stock Alerts At http://crwepicks.com/ ******************************************* THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY! Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment (read more) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) has previously received five hundred thousand shares compensation for 30 days of advertisement services and received an additional 1,000,000 shares 144 restricted stocks for a continuation of 6 months of advertisement and disseminating news, as well as $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB). Recently, Crown Equity Holdings, Inc has received an additional amount of 2,000,000 shares of free trading stock for 60 days media advertisement, web design and maintenance for Power 3 Medical Products Inc. (PWRM.OB) ******************************************* End
|
| ||||||||||||||||||||||||||||||||||||||||||||||
